BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic triple-negative breast cancer (TNBC) ineligible for immunotherapy, according ...
Rebecca Dent, MD, MSc, of the National Cancer Center in Singapore, gives insights on the use of antibody-drug conjugates (ADCs) in early breast cancer treatment. Rebecca Dent, MD, MSc, deputy CEO and ...
A national cohort study found that the incidence of triple-negative breast cancer (TNBC) is highest among Black women living in the most socioeconomically disadvantaged neighborhoods, and the ...
In patients with triple-negative breast cancer (TNBC), adding once‑weekly carboplatin to standard neoadjuvant taxane‑anthracycline chemotherapy was associated with a significant improvement in overall ...
Researchers from Nankai University and collaborating institutions have identified a novel proteolysis targeting chimera (PROTAC) molecule that effectively and selectively degrades multiple ...
Triple-negative breast cancer (TNBC) is a highly aggressive subtype affecting 15%-20% of breast cancer patients. TNBC patients harboring breast cancer susceptibility gene 1/2 (BRCA1/2) mutations have ...
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback